[Research of 10-23 DNAZyme inhibit the expression of eIF4E genes].
OBJECTIVE
To explore the possibility of 10-23DNAzyme becoming a new gene therapy for laryngeal carcinoma treatment at the cell level.


METHODS
Thiosthorothioate 10-23DNAzyme specific to eIF4E gene mRNA 1059 was designed and synthesized, and its inhibition effects on the expression of eIF4E gene in Hep-2 cells were observed.


RESULTS
The expression of eIF4E gene was remarkable depressed after Hep-2 cells was transfected by DNAzyme. The level of inhibiting eIF4E in hep-2 cells transfected by DNAzyme was lower than that by only lipofectamine 2000 transfected and Hep-2.


CONCLUSIONS
The expression of eIF4E gene in Hep-2 cells 10-23DNAzyme can be highly blocked. It is a specific and effective gene therapeutic means.
Teng
Bo
B
Department of Otolaryngology, Second Hospital of Jilin University,Changchun 130041, China. tengbo1975@163.com
Xin
Ding
D
Wen
Lianji
L
Cui
Shuxun
S
Jin
Chunshun
C
D017209:Apoptosis; D045744:Cell Line, Tumor; D021881:DNA, Catalytic / Q000235:genetics*; D004277:DNA, Single-Stranded / Q000235:genetics*; D039561:Eukaryotic Initiation Factor-4E / Q000235:genetics / Q000378:metabolism*; D015870:Gene Expression; D015316:Genetic Therapy; D006801:Humans; D007822:Laryngeal Neoplasms / Q000235:genetics*; D012333:RNA, Messenger / Q000235:genetics; D014162:Transfection